# Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

> **NCT05856695** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 67 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Carboplatin + Paclitaxel + Durvalumab

## Key facts

- **NCT ID:** NCT05856695
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-17
- **Primary completion:** 2026-02
- **Final completion:** 2028-02
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05856695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05856695, "Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05856695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*